Phase I/II Trial of Neoadjuvant Oregovomab-Based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir for Locally Advanced Pancreatic Adenocarcinoma

OBJECTIVES: Cancer antigen (CA)-125 influences progression, metastasis, and outcomes in pancreatic cancer (PC). This phase I/II trial () evaluated safety, efficacy, and immunologic correlates of chemoimmunotherapy (CIT) with oregovomab (anti–CA-125), followed by stereotactic body radiotherapy (SBRT)...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Clin Oncol
Autors principals: Lin, Chi, Verma, Vivek, Lazenby, Audrey, Ly, Quan P., Berim, Lyudmyla D., Schwarz, James K., Madiyalakan, Madi, Nicodemus, Christopher F., Hollingsworth, Michael A., Meza, Jane L., Are, Chandrakanth, Padussis, James, Grem, Jean L.
Format: Artigo
Idioma:Inglês
Publicat: 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6768754/
https://ncbi.nlm.nih.gov/pubmed/31513018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/COC.0000000000000599
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars